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Modelling the demographic impact of HIV/AIDS  
in South Africa and the likely impact of interventions  
Leigh F. Johnson 
1 
Rob E. Dorrington 
2 
Abstract 
This paper describes an approach to incorporating the impact of HIV/AIDS and the 
effects of HIV/AIDS prevention and treatment programmes into a cohort component 
projection model of the South African population. The modelled HIV-positive 
population is divided into clinical and treatment stages, and it is demonstrated that the 
age profile and morbidity profile of the HIV-positive population is changing 
significantly over time. HIV/AIDS is projected to have a substantial demographic 
impact in South Africa. Prevention programmes – social marketing, voluntary 
counselling and testing, prevention of mother-to-child transmission and improved 
treatment for sexually transmitted diseases – are unlikely to reduce AIDS mortality 
significantly in the short term. However, more immediate reductions in mortality can be 
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1. Introduction  
South Africa is one of the few African countries with nationally representative HIV 
prevalence data and good vital registration data (Department of Health 2004; Bradshaw 
et al. 2004). However, these data cannot provide planners with a direct measure of the 
demographic impact of HIV/AIDS or an indication of the likely future evolution of the 
epidemic. For this, mathematical models, calibrated to these data, are necessary. These 
models, if appropriately constructed, can also be used to assess the likely effect of 
different prevention and treatment programmes, as well as likely needs for treatment 
and orphan care, and are therefore an important tool in policy formulation. 
A large number of mathematical models have been developed to simulate the 
impact of HIV/AIDS and the likely effect of prevention and treatment programmes. 
These models can be classified into two broad groups: individual-based stochastic 
simulation models, which randomly generate events such as infection and death for 
each individual in the population; and deterministic models, which typically divide the 
population into cohorts of individuals, and compute average numbers of events in each 
cohort on the assumption that all individuals in a cohort share the same characteristics.  
Of the stochastic models that have been developed, most have focussed on 
simulating the effects of HIV prevention rather than treatment (Korenromp et al. 2000; 
Van der Ploeg et al. 1998; Bracher, Santow and Cotts Watkins 2004; Robinson et al. 
1995). Because of the heavy computational requirements associated with individual-
based simulation, populations simulated are typically limited in size to 10 000 to 20 000 
individuals. This results in a significant amount of stochastic variation, which makes it 
difficult to calibrate the model to HIV prevalence and mortality data (Korenromp et al. 
2000). In addition, these models require an extensive range of assumptions as input.  
Deterministic models tend to be used for larger populations and in situations where 
data for setting assumptions are limited. Many of these models have been used to 
illustrate the differences between the effects of HIV prevention and treatment 
programmes (Salomon et al. 2005; Stover et al. 2002; Nagelkerke et al. 2002). 
However, many of these models are based on very broad age divisions of the 
population, which makes them inappropriate for projecting the population over long 
periods. In some cases, the results of these simple deterministic models have been 
incorporated into cohort component projection models such as DemProj (Stover 2004), 
in an attempt to estimate the demographic impact of HIV/AIDS more accurately. 
However, Heuveline (2003) identifies a number of problems with this approach, 
including failure to allow for changes in the age profile of HIV cases over the course of 
the epidemic, difficulties in incorporating the effect of HIV on fertility, and difficulties 
in establishing parameters for a cohort component projection model in a hypothetical 
‘no AIDS’ scenario. Demographic Research: Volume 14, Article 22 
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The ASSA2002 AIDS and Demographic model is a combined cohort component 
projection and HIV/AIDS model, developed by the Actuarial Society of South Africa to 
estimate the impact of HIV/AIDS in South Africa. The basic structure of the earlier 
ASSA2000 version of the model has been described previously (Dorrington 2000). The 
objective of this paper is to describe how the basic cohort component projection model 
has been extended to model the demographic impact of HIV/AIDS, to describe how 
HIV prevention and treatment programmes are modelled, and to demonstrate the 
significance of these prevention and treatment programmes in demographic terms. 
 
 
2. Method  
The ASSA2002 model was developed from an earlier version of the model, ASSA2000, 
which did not allow for the effects of prevention and treatment programmes. It is 
assumed that the epidemic is started by the ‘importing’ of a number of infected 
individuals in 1985, a few years prior to the first reports of AIDS cases in the 
heterosexual population. The epidemic is modelled as being spread by heterosexual 
intercourse and mother-to-child transmission. Age-specific assumptions about the 
population profile in 1985, fertility, non-AIDS mortality and international migration are 
based on analyses of the 1970, 1996 and 2001 censuses, vital registration data from 
1985 onwards and the 1998 Demographic and Health Survey (DHS), and are not 
described here.  
The model has been programmed both in Excel/VBA and in Visual C++, and the 
Excel/VBA version is freely available online (Actuarial Society of South Africa 2004)
3. 
A user guide for the model (Dorrington, Johnson and Budlender 2004) is also available 
online. A separate model, which makes use of output from the AIDS and Demographic 
model, has been developed to estimate numbers of orphans from the ASSA2002 
outputs, and is described elsewhere (Johnson and Dorrington 2001). 
 
 
2.1 Modelling of sexual behaviour  
Individuals are assumed to be at risk of acquiring HIV through heterosexual contact 
between the ages of 14 and 59. Within this age band, individuals are split into four ‘risk 
groups’: a ‘PRO’ group, which represents sex workers and their frequent clients; a 
‘STD’ group, which represents individuals who are regularly infected with sexually 
transmitted diseases (STDs) although not frequently engaging in commercial sex; a 
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‘RSK’ group, consisting of individuals who are at risk of HIV infection although not 
regularly infected with other STDs; and a ‘NOT’ group, comprising individuals who are 
not at risk of infection (either because they are not sexually active or because they are in 
long-term mutually monogamous relationships). The assumed relative sizes of these 
risk groups and their sexual behaviour characteristics are shown in Table 1.  
The relative sizes of the risk groups are assumed to be the same for males and 
females, as are the relative frequencies of condom usage in each risk group. Male 
preferences regarding the risk group of their female partners, as well as average annual 
numbers of female partners, are determined to be consistent with the assumptions for 
females. Average fertility rates are assumed to apply to women in the RSK group, while 
women in the PRO and STD groups have fertility rates that are lower than the average 
by 60% and 30% respectively. This allows for the effects of higher contraceptive usage 
and STD incidence in the PRO and STD groups. 
Rates of condom use are assumed to be higher in the PRO and STD groups, as 
condoms tend to be used more frequently in short-term casual relationships (Van der 
Ryst et al. 2001; Williams et al. 2000; Department of Health 1999). The condom usage 
adjustment factors in Table 1 represent the factor by which the average age-specific 
 
Table 1:   Characteristics of risk groups 
 
  Female risk group  Male risk group 
  PRO STD RSK NOT  PRO STD RSK NOT 
% of 25-59 population in 
     risk group in 1985 
1%  20%  23% 56%  1%  20% 23% 56% 
Average annual number 
     of new partners 




%  of  new  partners  in            
     PRO group  0.75  0.2  0  -  0.8
* 0.26
* 0  - 




     RSK group  0  0.05  0.6  -  0  0.04
* 0.53
* - 
Average # coital acts per 
partnership if partner is in 
          
     PRO group  1  3  -  -  1  1  -  - 
     STD group  1  13  50  -  3  13  45  - 
     RSK group  -  45  95  -  -  50  95  - 
Condom usage  
     adjustment factor 
2 1.5  1 -  2 1.5  1 - 
Fertility adjustment factor  0.4  0.7  1  1.12
†  - - - - 
 
* Determined to be consistent with female assumptions. 
† Determined to be such that the fertility adjustment factors, when weighted 
by the proportion of the sexually experienced population in each risk group, averaged to 1. Demographic Research: Volume 14, Article 22 
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rates of condom usage are multiplied to obtain age-specific condom usage rates in each 
risk group. The average age-specific rates for 1998 were set to be the same as those 
recorded in the 1998 DHS, and are shown in Table 2. Frequency of condom use appears 
to have increased substantially in recent years (Human Sciences Research Council 
2002; Reproductive Health Research Unit 2004), and it is assumed that this is the result 
of social marketing programmes. In the absence of these social marketing programmes, 
it is assumed that condom usage would have remained constant at half the level 
observed in 1998, in all years.  
 
Table 2:   Age-specific behavioural assumptions    
 





experienced Average  Variance 
15-19 9.8%  19.6%  46%  24.31  19.80 
20-24 7.2%  14.4%  90%  28.84  25.24 
25-29 3.8% 7.6%  100%  32.95  49.43 
30-34 3.3% 6.6%  100%  37.63  55.10 
35-39 1.5% 3.0%  100%  42.69  70.99 
40-44 1.5% 3.0%  100%  47.04  66.86 
45-49 1.5% 3.0%  100%  51.45  56.05 
50-54 1.5% 3.0%  100%  55.86
† 45.24
† 




* Allowing for the effect of social marketing programmes. 
† Extrapolated from estimates at younger ages 
 
Individuals become sexually active between the ages of 13 and 25. At age 14, it is 
assumed that 10% of individuals are sexually experienced, and 12% of the remainder 
are assumed to become sexually experienced in the next year. The annual probability of 
becoming sexually experienced is assumed to increase linearly with respect to age, until 
all individuals are sexually experienced at age 25. These assumptions were set to 
produce rates of sexual experience consistent with those observed in surveys 
(Reproductive Health Research Unit 2004; Department of Health 1999), and are shown 
in Table 2. The same sexual debut assumptions are used for males and females, as 
surveys do not suggest that there is a significant difference in sexual experience 
between males and females at young ages (Williams et al. 2000; Reproductive Health 
Research Unit 2004). Individuals remain in the NOT group until they become sexually 
experienced, after which they either remain in the NOT group or get moved into the 
other risk groups. The model assumes that people do not change risk group after sexual 
debut. Johnson & Dorrington: Modelling the demographic impact of HIV/AIDS in South Africa  
546   http://www.demographic-research.org 
Although individuals cannot move between risk groups after sexual debut, 
allowance is made for rates of partnership formation and coital frequencies to vary with 
age. For females, a sexual activity index is constructed using the formula 
 
() () ()
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S     (1) 
 
where  x S  is the multiple by which the average number of partners and the average 
number of coital acts per partnership increases at age x. The shape parameter (0.005) 
and position parameter (13) were set at levels that ensured patterns of HIV prevalence 
by age were as far as possible consistent with those observed in surveys (Department of 
Health 2004).  The mean age of male partners and the variance of male partner ages 
were estimated from the 1998 DHS, for each five-year age band, and are shown in 
Table 2. For a woman aged x, the distribution of male partner ages,  () x y f |,  i s  
assumed to be gamma, with mean and variance determined from the values in Table 2. 
Thus, 
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2.2 Modelling of HIV survival  
In the absence of treatment and other interventions, adult HIV survival is modelled 
using a four-stage model of HIV disease progression, with the four stages 
corresponding to the four stages of the WHO Clinical Staging System (WHO 
International Collaborating Group for the study of the WHO Staging System 1993). The 
effect of highly active antiretroviral treatment (HAART) is modelled by adding two 
stages to the basic four-stage model of HIV survival: stage 5 represents individuals 
currently on HAART, and stage 6 represents individuals who have discontinued 
HAART. Individuals are assumed to start treatment at the time of their first AIDS-
defining illness, i.e. on progressing from HIV stage 3 to HIV stage 4. For each of stages 
1 to 4, a record is kept of the proportion of individuals who have received voluntary 
counselling and testing (VCT) and know their HIV status. All individuals who are on 
HAART or who were previously on HAART are assumed to know their HIV status. 
This model of disease progression is represented in Figure 1. 
The total time from HIV infection to death in adults has been found to depend on 
the age at HIV infection (Collaborative Group on AIDS Incubation and HIV Survival 
2000). AIDS mortality rates and proportions of individuals in each of the six disease 
stages are therefore calculated at each integer duration of HIV infection for three 
infection ages: 19, 29 and 39. For other ages at infection, AIDS mortality rates and 
proportions in different stages, at integer durations of infection, are interpolated or 
extrapolated from those calculated at the three pivot ages. The mean time from HIV 
infection to death, in the absence of HAART, is assumed to be 12 years for individuals 
infected at age 19, 11 years for individuals infected at age 29 and 9.5 years for 
individuals infected at age 39 or older (median survival times are roughly half a year 
shorter in each case). These assumptions are set to be consistent with survival rates in 
the developed world, as local studies do not suggest that HIV survival in South Africa 
differs substantially from that in the developed world (Glynn et al. 2005; Maartens et 
al. 1997; Badri et al. 2004), and lower HIV survival assumptions tend to produce higher 
estimates of the number of deaths than have been observed in South Africa. 
Estimates of the proportion of adult HIV survival time spent in each of WHO 
stages 1 to 4, in the absence of HAART, are derived from application of simple Markov 
models to survival data collected from a number of settings (Morgan et al. 2002a; 
Morgan et al. 2002b; Malamba et al. 1999; Deschamps et al. 2000; Longini et al. 1989; 
Davidse 2000). The estimated proportions, shown in Table 3, are used to estimate the 
mean time spent in each stage of disease, for each of the three pivot ages. The time 
spent in stage t of disease is assumed to follow a Weibull distribution, parameterized in 
terms of a median ( t m ) and shape parameter ( t φ ), both of which are related to the mean 
( t µ ) by the following formulae: Johnson & Dorrington: Modelling the demographic impact of HIV/AIDS in South Africa  
548   http://www.demographic-research.org 
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As equation (5) shows, the means and shape parameters for the different stages are 
assumed to be linearly related. Parameter  4 φ  is set at 1, and parameter b is set at 0.35, 
in order to replicate the ‘shape’ of the survivor functions observed in the developed 
world (Collaborative Group on AIDS Incubation and HIV Survival 2000). 
 
Table 3:   Stage-specific parameters 
 
Effect of VCT 
 










Reduction in % 
of sex acts 
unprotected 
WHO stage 1  27.0%  1  19%  36% 
WHO stage 2  19.8%  1  19%  36% 
WHO stage 3  35.8%  0.65  19%  36% 
WHO stage 4  17.4%  0.25  31%  53% 
Stage 5 (on 
HAART) 
- 0.8  31% 53% 
Stage 6 (off 
HAART) 
- 0.25  31% 53% 
    
* Assuming HAART is not available. 
 
As shown in Figure 1, individuals on HAART ultimately either discontinue 
treatment or die while on treatment. The probabilities of AIDS death and 
discontinuation of HAART in the first six months on HAART (0.0821 and 0.0914 
respectively) are assumed to be particularly high. Thereafter, annual probabilities of 
AIDS death while on HAART and discontinuation of HAART (both 0.0584) are 
assumed to remain constant. After discontinuing HAART, individuals are assumed to 
experience the same AIDS mortality rates as untreated individuals in HIV stage 4. 
These assumptions result in a decline in AIDS mortality rates consistent with the 70 to 
80% reductions in AIDS mortality rates observed after starting HAART in various 
studies (Palella et al. 1998; Murphy et al. 2001; Jordan et al. 2002). These and other 
studies (Badri et al. 2004) also suggest a 60 to 85% reduction in the incidence of 
opportunistic infections after starting HAART. It is therefore assumed that only 25% of 
individuals in stages 5 and 6 are classified as ‘AIDS sick’. Demographic Research: Volume 14, Article 22 
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Figure 1:  Model of HIV disease progression in adults, incorporating the  
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As individuals enter the later stages of HIV disease, coital frequencies decrease 
due to increased morbidity (Ross et al. 2004; Terceira et al. 2003; Hankins, Tran and 
Lapointe 1998; Wilson et al. 2004). The frequency of sex in stage t, expressed as a 
multiple of the frequency of sex in stages 1 and 2 (the asymptomatic stages), is set to 
vary according to the severity of symptoms in stage t. The assumed values of these 
multiples are shown in Table 3. Further changes in sexual behaviour are assumed to 
occur when HIV-infected individuals learn their HIV status through VCT programmes. 
Table 3 also shows the assumed reductions in the frequency of sex and in the proportion 
of coital acts that are unprotected in HIV-positive individuals who know their HIV 




2.3 Modelling of sexual transmission  
The parameter  () y Ttij  is defined as the probability that an HIV-positive y-year old 
woman, in stage t of disease and in risk group j, transmits the virus to a partner in risk 
group i in a single act of sex. The parameter is calculated using the formula 
 
() () () 1 1 1 () tij ij t j t T yr I c y R e  =⋅ −−−       (7) 
 
where  
•   ij r  is the average probability of transmission from an HIV-positive female in risk 
group j to an HIV-negative male in risk group i, in a single act of unprotected sex;  
•   t I  is the factor by which  ij r  is multiplied if the HIV-positive female is in stage t of 
disease; 
•   () y c j  is the probability that a sero-discordant couple use a condom when the index 
partner is aged y and in risk group j; 
•   t R  is the factor by which the proportion of sex acts that are unprotected is multiplied 
in stage t of disease (taking into account the effect of knowledge of HIV status); and 
•  e is the probability that a condom is effective in preventing HIV transmission in a 
single act of sex (assumed to be 0.95). 
A similar formula is used to define the probability of male-to-female transmission, 
with male-specific parameters  () y Ttij
* , 
*
ij r  and 
*
t R  replacing  () y Ttij ,  ij r  and  t R  
respectively.  Demographic Research: Volume 14, Article 22 
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On the basis of studies of HIV transmission in stable sero-discordant partnerships 
(Downs and De Vincenzi 1996; Peterman et al. 1988; Wiley, Herschkorn and Padian 
1989; Gray et al. 2001), the parameters  33 r  and 
*
33 r  are set at 0.001 and 0.002 
respectively (these parameters apply when both partners are in the RSK group). To 
reflect the effect of STDs on HIV transmission, it is assumed that transmission 
probabilities are higher when both partners are either in the PRO or STD group 








11 = = = = r r r r ), or one partner is in the 




23 = = r r ). 
HIV transmission probabilities are assumed to vary according to the stage of 
disease, with transmission being most efficient in those stages with the highest average 
levels of viral load. Based on estimates of change in viral load over the course of HIV 
infection (Kassa et al. 1999; Hubert et al. 2000), and an assumed 3-fold increase in HIV 
transmissibility per log increase in viral load (Quinn et al. 2000; Fideli et al. 2001), the 
values of  1 I ,  2 I ,  3 I  and  4 I  are set at 0.5, 0.4., 1.5 and 2.9 respectively. It is assumed 
that HIV viral load while on antiretroviral treatment is 1.76 log below that in stage 4 
(Jordan et al. 2002), and the value of  5 I  has therefore been set at 0.4 (= 
76 . 1 3 9 . 2
− × ). 
After discontinuation of treatment, levels of infectiousness are assumed to return to 
those in untreated AIDS (i.e.  6 I = 4 I ). 
Probabilities of HIV infection are calculated at annual intervals. The probability 
that a female aged x, in risk group i, becomes infected in a given year is calculated as 
 




























1 1 ) ( | ) ( 1 1    (8) 
where 
•   ) (x a  is the factor by which the per-partnership transmission probability is multiplied 
in women aged x; 
•   ij w  is the proportion of male partners who are in risk group j (Table 1); 
•   ) (y ptj  is the proportion of male partners (aged y and in risk group j) who are HIV-
positive and in stage t of disease; 
•   ij n  is the number of coital acts per partnership between a female in risk group i and a 
male in risk group j (Table 1); 
•   t D  is the factor by which the coital frequency is multiplied in stage t of disease 
(taking into account the effect of disease symptoms and knowledge of HIV status); 
•   i P  is the average annual number of partners for a woman in group i (Table 1). Johnson & Dorrington: Modelling the demographic impact of HIV/AIDS in South Africa  
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A similar formula for the annual infection probability is used for males, with 
female-specific parameters being replaced by male-specific parameters. 
Studies suggest that transmission probabilities are particularly high in women 
under the age of 25 (Carpenter et al. 1999), possibly as a result of the high prevalence 
of cervical ectopy in young women (Plourde et al. 1994). The factor  ) (x a  is therefore 











25 20 1 . 1









     (9) 
 
The factor  ) (x a  is omitted from the calculation of female-to-male transmission. 
 
 
2.4 Modelling vertical transmission and paediatric HIV survival  
Two distinct patterns of mother-to-child transmission of HIV are modelled: 
intrauterine/intrapartum transmission (transmission before or during birth) and 
transmission through breast milk. It is assumed that in the absence of intervention, 20% 
of HIV-positive mothers would transmit the virus to their child before or during birth 
(Nduati et al. 2000; Dabis et al. 1999; Coutsoudis et al. 1999), and 16% of the 
remainder would subsequently transmit the virus to their child as a result of 
breastfeeding (Miotti et al. 1999; Nduati et al. 2000). The age at infection through 
breast milk is assumed to be uniformly distributed over the first year of life, with equal 
numbers of children infected through breast milk in the first six months of life and in 
the second six months. 
The modelling of paediatric HIV survival is similar to that of adult HIV survival, 
with two important differences. Firstly, the four-stage WHO clinical staging system for 
adults is replaced with a simple two-stage system (pre-AIDS and AIDS). Secondly, 
survival assumptions differ for children who are infected before or at birth and children 
infected through breast milk, with children infected intrauterine/intrapartum being 
assumed to experience more rapid disease progression. As in adults, the time spent in 
each of the non-antiretroviral stages is assumed to follow a Weibull distribution, and 
antiretroviral treatment is assumed to start at the time that children experience their first 
AIDS-defining illness. In common with the adult survival model, the shape parameter 
for the Weibull distribution is set at 1 for the AIDS stage, and the distribution of 
survival times in the ‘off treatment’ stage is assumed to be the same as that for the 
untreated AIDS stage. Demographic Research: Volume 14, Article 22 
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Assumptions about the time spent in each stage were set so that the aggregate 
paediatric HIV survivor function was roughly consistent with the ‘upper limit’ on the 
survivor function estimated by Marston et al (2005). (The upper limit was chosen 
instead of the best fit to the data, to be consistent with the high assumed rates of adult 
HIV survival in South Africa, relative to the rates observed in other developing 
countries.) This survivor function is a double Weibull distribution, with ‘fast 
progression’ and ‘slow progression’ components (assumed to be appropriate to 
intrauterine/intrapartum infections and breast milk infections respectively). For children 
infected before or during birth, the time spent in the pre-AIDS stage follows a Weibull 
distribution with median 0.5 years and shape parameter 0.7, and the median time in the 
AIDS stage is 0.3 years (Hussey et al. 1998). For children infected by breast milk, the 
pre-AIDS survivor function is Weibull with median 7.8 years and shape parameter 5.5, 
and the median survival time in the AIDS stage is 0.93 years. 
 
 
2.5 Modelling of prevention and treatment programmes  
Five intervention programmes are modelled: VCT, prevention of mother-to-child 
transmission (PMTCT), HAART, improved STD treatment, and social marketing. 
Assumptions are made about the year in which each programme is introduced and the 
proportion of the population that has access to the treatment or prevention service in 
each subsequent year (Table 4). These assumptions reflect the actual experience in 
South Africa to date, based on published and unpublished data discussed below. 
VCT is assumed to result in a reduction in unprotected sex in individuals who test 
HIV-positive, as described previously. It is assumed that if VCT was readily accessible 
and well-publicized, 6% of adults at risk of infection would seek VCT per annum (Scott 
et al. 2005; Fylkesnes et al. 1999). It is further assumed that 80% of women receiving 
antenatal care agree to VCT if the service is offered to them as part of a PMTCT 
programme (Abdullah et al. 2001). Adults also automatically receive VCT before 
starting HAART if they are not already aware of their HIV status. The proportions in 
the VCT row of Table 4 are the proportions of adults with access to VCT and awareness 
of the VCT programmes on offer, based on estimates of VCT access in the South 
African public sector in 2002 (Ramkissoon et al. 2004). 
The proportions in the PMTCT row in Table 4 are the proportions of pregnant 
women assumed to be offered PMTCT in each year, based on early reports 
(Ramkissoon et al. 2004; McCoy et al. 2002). It is assumed that if women agree to 
VCT, all of those who test positive receive short-course antiretroviral treatment to 
prevent perinatal transmission of HIV. The regimen currently offered is the HIVNET 
012 regimen, which is assumed to result in a 47% reduction in intrauterine/intrapartum Johnson & Dorrington: Modelling the demographic impact of HIV/AIDS in South Africa  
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transmission (Guay et al. 1999). It is also assumed that women participating in the 
PMTCT programme have a 50% lower risk of transmitting the virus to their child 
through breast milk, as a result of the promotion of formula milk and exclusive 
breastfeeding to these mothers. 
 
Table 4:   Rates of intervention phase-in    
 





Yr 1  Yr 2  Yr 3  Yr 4  Yr 5  Yr 6  Yr 7  Yr 8  Yr 9  Yr 10* 
VCT  1995  8% 17% 25% 33% 42% 50% 58% 67% 75%  83% 
PMTCT  2001  10% 40% 60% 80% 90% 90% 90% 90% 90%  90% 
H A A R T                
‘Constrained’  2000  2%  4%  6%  8% 17% 25% 34% 42% 50%  50% 
‘Optimistic’  2000  2%  4%  6%  8% 25% 41% 58% 74% 90%  90% 
STD  treatment 1994  10% 30% 50% 80% 90% 95% 95% 95% 95%  95% 
Social  marketing  1994  3%  7% 12% 20% 33% 50% 66% 80% 90%  95% 
 
* Rates of phase-in achieved by the 10
th year are assumed to be maintained at the same level in all subsequent years. 
 
 
HAART is assumed to have benefits both in terms of improved survival and 
reduced HIV infectiousness, as previously described. The proportions in the HAART 
rows in Table 4 are the proportions of new AIDS cases starting antiretroviral treatment 
in each year. The assumptions prior to 2004 are based on historical estimates of 
numbers treated, mostly in the private health sector (McLeod, Achmat and Stein 2003). 
Much uncertainty exists, however, regarding the likely future pace and extent of 
antiretroviral treatment rollout. Two treatment scenarios are therefore considered: a 
‘constrained’ scenario in which ultimately only 50% of new AIDS cases are able to 
access treatment, and an ‘optimistic’ scenario in which the percentage of new AIDS 
cases starting HAART rises to 90%.  
Improved STD treatment in South Africa is mostly the result of syndromic 
management protocols in public STD clinics. This began in 1994, and by 1999 virtually 
all public STD clinics were following syndromic management guidelines (Dr D. 
Coetzee, University of Cape Town, personal communication). This improvement is 
assumed to result in a reduction in average HIV transmission probabilities: by 15% 
when both partners are in either the PRO or STD group, by 10% when one partner is in 
the STD group and the other in the RSK group, and by 5% when both partners are in 
the RSK group. The reductions assumed are thus commensurate with the STD 
prevalence rates in the different risk groups. The reductions assumed are also 
conservative, as there is little evidence of similar improvements in STD treatment in the 
private health sector, which treats roughly half of all STD cases (Schneider et al. 2001).  Demographic Research: Volume 14, Article 22 
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Social marketing is assumed to have resulted in increased condom usage, as 
previously described. Based on the significant improvements in condom usage that have 
been observed, it is assumed that condom usage is three times more common in 
individuals with good knowledge of HIV/AIDS and easy access to condoms than in 
those who have little knowledge of the disease or poor access to condoms. The 
proportions in the ‘Social marketing’ row of Table 4 are the proportions of sexually 
active adults who are exposed to social marketing on a regular basis in each year, who 
are assumed to have good knowledge of HIV/AIDS and easy access to condoms. These 
were set to be such that the average rates of condom usage in 1998 and 2002 were 
roughly consistent with those estimated in surveys (Department of Health 1999; Human 
Sciences Research Council 2002). The proportions are also consistent with the rise in 
numbers of male condoms distributed since 1994 (Myer 2005). 
In the analysis that follows, four intervention scenarios are considered:  
•   ‘no intervention’ scenario: none of the prevention and treatment programmes 
described above are introduced at any time,  
•   ‘prevention only’ scenario: assumes the same rates of intervention phase-in as in 
Table 4, except that there is no HAART rollout,  
•   ‘constrained’ scenario: prevention programmes are coupled with a constrained 
HAART rollout, and  
•   ‘optimistic’ scenario: prevention programmes are coupled with an optimistic 
HAART rollout.  




2.6 Calibration  
Model estimates of numbers of adult deaths, by sex and five-year age band, are 
compared with empirically derived estimates of numbers of deaths for each year from 
1996 to 2002 (Dorrington, Moultrie and Timæus 2004). (Vital registration of adult 
deaths is estimated to be about 85% complete for the period 1996 to 2001, and thus the 
estimated numbers of deaths, corrected for incompleteness, can be considered to be 
fairly reliable.) Model estimates of HIV prevalence in pregnant women using public 
antenatal clinics, by five-year age band, are compared with those observed in the 
nationally representative antenatal clinic surveys, for each year from 1991 to 2002. In 
order to produce model estimates of prevalence in pregnant women attending public 
clinics, it is necessary to allow for the effect of HIV on fertility, correlation between 
pregnancy and HIV risk behaviour at young ages, and socioeconomic bias in the 
antenatal sample. Johnson & Dorrington: Modelling the demographic impact of HIV/AIDS in South Africa  
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To obtain the age-specific fertility rate of an HIV-positive woman aged x, who has 
been infected for d years, the fertility rate in HIV-negative women of the same age is 




x x B A − 1 ,         ( 1 0 )  
 
where  x B  is the percentage by which fertility reduces per year of HIV infection, and 
x A  is a factor introduced to allow for the positive correlation between childbearing and 
risk of HIV infection at young ages. These parameters were set to be such that the ratios 
of antenatal prevalence to general female prevalence in each five-year age band were 
approximately consistent with those ratios estimated from southern African surveys 
(Gregson et al. 2002; Human Sciences Research Council 2002). Parameter  x B  was set 
at 4% for all x.  14 A  was set at 1.5, with a 20% reduction in the difference between  x A  
and 1 for each year of increase in age. 
The model estimates of prevalence in pregnant females were multiplied by 
‘antenatal adjustment factors’ to allow for the under-representation of women of higher 
socio-economic status in the public antenatal clinic survey. These factors were derived 
based on health-seeking behaviour data by age and race from the 1998 DHS, together 
with unpublished estimates of HIV prevalence by age, race and medical scheme 
membership, derived by the authors. The antenatal adjustment factors for the different 
five-year age bands vary between 1.08 and 1.18. 
 
 
3. Results  
Model estimates of HIV prevalence in antenatal clinics and numbers of deaths in the 
constrained scenario are compared with empirical estimates in Figures 2 and 3 
respectively. The correspondence between observed and modelled antenatal prevalence 
in recent years is close, with the model estimating a prevalence of 25.6% in pregnant 
women attending public clinics in 2002, just less than the prevalence of 26.5% observed 
in the survey. The modelled prevalence in the earlier years is deliberately set below the 
reported antenatal prevalence, to allow for the bias towards urban clinics in the early 
antenatal surveys, which was only corrected when new survey protocols were 
introduced between 1997 and 2000 (Department of Health 2001). Comparison of 
prevalence by age group shows a levelling in the observed 15-24 prevalence in recent 
years and a continued rise in 25-29 prevalence, neither of which is closely reproduced 
by the model (results not shown).  Demographic Research: Volume 14, Article 22 
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Figure 2:   Observed and modelled HIV prevalence in women attending  































































95% confidence intervals are shown for antenatal survey estimates after 1997. 
 
 
Estimates of numbers of deaths between the ages of 15 and 59 are close to those 
derived empirically, although the model appears to over-estimate the mortality to some 
extent in males between the ages of 35 and 45 and in females between the ages of 25 
and 45. 
The results of the ASSA2002 model for the four scenarios considered are shown in 
Figure 4. In the absence of interventions, it is estimated that the HIV incidence rate 
would have risen to its highest level in 1998 and thereafter declined (Figure 4a), due to 
decreasing numbers of HIV-susceptible individuals in the high-risk groups. Prevention 
programmes have led to some reduction in HIV incidence, but HIV incidence remains 
high in all three intervention scenarios. The introduction of HAART is expected to have 
little impact on HIV incidence, with the difference in incidence in the ‘prevention only’ 
and ‘optimistic’ scenarios lying below 0.1% in all years. HAART is, however, expected 
to have a significant impact on HIV prevalence, due to the improved survival prospects 
of infected individuals. The effect of prevention programmes is to reduce HIV 
prevalence in 2005 by roughly 2% (Figure 4b). By 2020, the prevalence expected if 
prevention is not coupled with HAART is well below that which would be expected if 
prevention was coupled with a high level of HAART rollout. Johnson & Dorrington: Modelling the demographic impact of HIV/AIDS in South Africa  
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Figure 3:   Modelled and empirically derived estimates of male  

























Model estimates (solid diamonds) and empirically derived estimates (open squares) are shown for each five-year age band in the 15 
to 59 age group. Demographic Research: Volume 14, Article 22 
http://www.demographic-research.org 559 
Figure 4c shows the increase in the crude mortality rate due to AIDS, or the 
percentage of the population dying due to AIDS in each year. By 2010, there is 
significant divergence between the four scenarios, with the increase in the crude 
mortality rate due to AIDS being more than twice as high in the ‘no intervention’ 
scenario as in the ‘optimistic’ scenario. Over the longer term, however, the differences 
between the three intervention scenarios diminish, due to the assumed limited duration 
of the HAART survival benefit. A similar trend is observed in respect of the life 
expectancy at birth (Figure 4d). In 2010, life expectancy is projected to be almost seven 
years higher in the ‘optimistic’ scenario than in the ‘prevention only’ scenario. By 
2020, however, the life expectancy in the ‘optimistic’ scenario is projected to exceed 
that in the ‘prevention only’ scenario by only three years. 
The child mortality rate (number of deaths per 1 000 births in the first five years of 
life) is also significantly affected by HIV/AIDS prevention and treatment. In the 
absence of intervention, this rate would be expected to rise by roughly 30 per 1 000 
from 1990 to 2010 (Figure 4e). As a result of prevention programmes (mostly PMTCT), 
there is a reduction of almost 25 deaths per 1 000 births in 2010 and subsequent years, 
relative to the ‘no intervention’ scenario. With the inclusion of HAART in the 
intervention package, even greater reductions in child mortality would be expected.  
Coinciding with the rise in AIDS mortality are rapid increases in the percentage of 
children whose mothers have died (maternal orphans). It is expected that in the absence 
of interventions, the percentage of children under the age of 18 whose mothers have 
died would increase more than five-fold between 1990 and 2015 (Figure 4f). Prevention 
programmes have little impact on rates of orphanhood, as reductions in orphanhood due 
to reduced adult mortality are largely offset by increases in orphanhood due to lower 
rates of mother-to-child transmission. However, the introduction of HAART has a 
significant impact on orphan numbers. The proportion of children aged less than 18 
who are maternally orphaned in 2015 would, in the ‘optimistic’ scenario, be only two 
thirds of that in the ‘no intervention’ scenario. 
Figure 5 shows trends in the age profile of newly infected individuals and trends in 
the morbidity profile of the infected adult population, for the ‘no intervention’ and 
‘optimistic’ scenarios. In 1995, less than one in five HIV infections are estimated to 
have been acquired by infants, from their infected mothers, or by teenagers, through 
sexual exposure. As the epidemic progresses, the proportion of new infections 
occurring below the age of 20 increases, due to ‘saturation’ of the epidemic at older 
ages. In the ‘no intervention’ scenario, it is estimated that almost half of new HIV 
infections occur below the age of 20 by 2020 (Figure 5a). This proportion is reduced in 
the  ‘optimistic’ scenario (Figure 5b), partly because of reduced mother-to-child 
transmission, and partly because reductions in unprotected sex lead to longer intervals 
between sexual debut and HIV infection. Johnson & Dorrington: Modelling the demographic impact of HIV/AIDS in South Africa  
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Figure 4:   HIV incidence, HIV prevalence and impact of HIV/AIDS  













































































































































































































































































































































* The percentage of children maternally orphaned is defined here as the proportion of children under the age of 18 who have lost 




The morbidity profile of the HIV-infected adult population also changes over the 
course of the epidemic. In 1995, almost 90% of all HIV-positive adults were in WHO 
stages 1 and 2, the asymptomatic stages of disease. This asymptomatic proportion is 
expected to decline to roughly a half in the ‘no intervention’ scenario and to a third in 
the  ‘optimistic’ scenario, by 2015 (Figures 5c and 5d). The proportion which is Demographic Research: Volume 14, Article 22 
http://www.demographic-research.org 561 
symptomatic and untreated (stages 3 and 4) in 2015 also differs substantially between 
the ‘no intervention’ scenario and the ‘optimistic’ scenario. 
The morbidity profile in 2015 can be further analysed by age (Figure 6). Although 
Figure 2b shows similar aggregate levels of HIV prevalence in 2015 in the ‘no 
intervention’ and ‘optimistic’ scenarios, there are significant differences between the 
two scenarios in terms of the age profile of the infected population. Below the age of 
30, HIV prevalence is higher in the ‘no intervention’ scenario than in the ‘optimistic’ 
scenario, due to the impact of prevention programmes in the latter. Over the age of 30, 
however, HIV prevalence is higher in the ‘optimistic’ scenario, due partly to the greater 
survival under HAART and partly to the shifting of HIV incidence to the older ages. 
Most infections below the age of 25 are asymptomatic (WHO stages 1 and 2), as they 
are recently acquired. The need for HAART is likely to be greatest between the ages of 




Figure 5:   Trends in the age profile of new HIV infections and the  
      morbidity profile of adult HIV infections, for the ‘no  
      intervention’ and ‘optimistic’ scenarios 
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Adult infections are grouped according to WHO clinical stage, with ‘HAART’ representing individuals who either are on treatment or 
have discontinued treatment. Johnson & Dorrington: Modelling the demographic impact of HIV/AIDS in South Africa  
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Figure 6:   Percentage of population infected by age, split by disease stage,  
      in 2015, for the ‘no intervention’ and ‘optimistic’ scenarios 




















































Adult infections are grouped according to WHO clinical stage, with ‘HAART’ representing individuals who either are on treatment or 
have discontinued treatment. 
 
 
4. Discussion  
The ASSA2002 model confirms that HIV/AIDS is having a significant demographic 
impact in South Africa. The ASSA2002 model also demonstrates that the prevention 
and treatment programmes that have been and are being introduced can significantly Demographic Research: Volume 14, Article 22 
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modify this demographic impact. Even when interventions do not substantially alter 
HIV prevalence, they can result in a shift of HIV incidence from younger to older ages, 
as well as an extension of HIV survival, both of which reduce the years of life lost due 
to HIV/AIDS. 
HIV prevention programmes appear to have had a modest impact on HIV 
incidence, with much of the reduction in HIV incidence taking place in the absence of 
prevention programmes. HAART is expected to have little impact on HIV incidence, 
but further sensitivity testing is necessary to check the robustness of this conclusion, 
particularly as the model does not currently assume any change in utilization of VCT or 
any change in sexual behaviour in HIV-negative individuals after HAART becomes 
available. Other models suggest that HAART will lead to a reduction in HIV prevalence 
(Nagelkerke et al. 2002; Boily et al. 2004; Gray et al. 2003), reflecting a significant 
positive effect of HAART on HIV incidence. The ASSA2002 model predicts a less 
significant preventative benefit from HAART because it assumes a slower phase-in of 
the intervention and because it assumes HAART is initiated in later stages of HIV 
disease.  
South Africa would still be experiencing significant declines in life expectancy had 
interventions not been introduced. Prevention programmes have not had significant 
effects on mortality in the short term, though PMTCT is estimated to have contributed 
significantly to declines in the child mortality rate. More immediate reductions in 
mortality are observed when HAART is introduced. However, as other models have 
shown (Salomon et al. 2005), the difference in mortality rates between ‘high HAART 
coverage’ and ‘low HAART coverage’ scenarios diminishes over the longer term, due 
to the limited survival benefit from HAART. HAART has a more sustained benefit in 
terms of levels of orphanhood, as HAART defers mortality of parents to those ages at 
which their children have ceased to be dependent on them. 
The ASSA2002 model is unique in modelling the profile of the HIV-positive 
population by WHO clinical stage, and this model output has proved useful in assessing 
the burden of disease due to HIV/AIDS (Bradshaw et al. 2003) as well as the costs of 
treatment and care for HIV/AIDS (Geffen, Nattrass and Raubenheimer 2003). Although 
HIV prevalence rates and AIDS mortality rates appear to be levelling off in the 
‘constrained’ scenario, an increasingly high proportion of infected individuals are either 
symptomatic (WHO stage 3 or 4) or on HAART. The need for treatment is greatest over 
the age of 25, while an increasingly high proportion of new infections are occurring 
below the age of 25. This suggests that prevention programmes need to be tailored to 
the youth, while treatment literacy and treatment screening would be particularly 
appropriate in older age groups. 
A strength of the ASSA2002 model is that it is calibrated to both HIV prevalence 
data and vital registration data, and produces results roughly consistent with both. Johnson & Dorrington: Modelling the demographic impact of HIV/AIDS in South Africa  
564   http://www.demographic-research.org 
However, the consistency is poor in some age groups. Extensive uncertainty analysis of 
the ASSA2002 model has failed to identify parameter combinations that give 
significantly improved fits to the age pattern of HIV prevalence and mortality, although 
correspondence with observed HIV prevalence in the 15 to 19 age group improves 
when it is assumed that social marketing programmes lead to reductions in rates of 
partner change (Johnson, Dorrington and Matthews 2006). It is therefore possible that 
the effects of social marketing are not limited to condom usage, as assumed here. The 
correspondence with the observed 15 to 24 prevalence might also be improved if the 
model were adapted to allow for greater effectiveness of STD treatment at young ages, 
when curable STDs are relatively more prevalent (Buvé et al. 2001) and incurable 
STDs relatively less prevalent (Smith and Robinson 2002). Correspondence with 
reported male deaths in the 35 to 44 age group might also be improved if allowance 
were made for higher rates of antiretroviral access in this group, linked to higher rates 
of medical scheme membership (Department of Health 1999). Calibration of AIDS 
models to data in five-year age bands can therefore yield important hypotheses about 
the effects of interventions and how they differ in relation to age and sex. 
In the ASSA2002 model, approximate consistency between model outputs and 
reported levels of HIV prevalence and mortality is achieved mainly through changes to 
assumed proportions of the sexually active population in the four risk groups and 
changes to average annual numbers of partners in these risk groups. However, no 
reliable empirical data exist that can be used to verify these sexual behaviour 
assumptions. There is thus considerable uncertainty regarding sexual behaviour 
parameters, in addition to the general uncertainty regarding other model parameters. A 
Bayesian analysis of South African HIV prevalence and vital registration data, based on 
the ASSA2002 model, has shown that a wide range of sexual behaviour assumptions 
can produce model outputs consistent with these HIV prevalence and vital registration 
data (Johnson,  Dorrington and Matthews 2006). The Bayesian analysis also 
demonstrated that the model outputs were broadly consistent with male and female HIV 
prevalence data and mortality data, in spite of the proportions of the population in the 
risk groups being set at the same level for males and females. 
A limitation of the model is that HIV transmission probabilities are calculated on 
an annual basis. This makes it impractical to allow for transmission dynamics that 
operate over short time periods. For example, the period of high HIV viraemia around 
seroconversion lasts for only a few months, but is potentially very significant in the 
spread of HIV (Pilcher et al. 2004). STDs are also often only of short duration, but play 
an important role in increasing HIV susceptibility and HIV infectiousness while present 
(Røttingen, Cameron and Garnett 2001). The modelling of the effect of improved STD 
treatment in ASSA2002 is therefore of necessity simplistic, and models with shorter Demographic Research: Volume 14, Article 22 
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time steps are needed to simulate the interactions between HIV and other STDs more 
accurately. 
Many uncertainties also apply in the modelling of other interventions. For 
example, the effectiveness of PMTCT programmes may well improve in future if 
zidovudine is used increasingly in combination with nevirapine, as is already happening 
in parts of the country (Eley 2005). Efficacy of HAART may also differ from that 
assumed here, as the evidence used in setting the HAART assumptions is drawn mostly 
from studies with short follow-up. It is also possible that utilization of counselling and 
testing services may increase beyond the levels assumed here, particularly with routine 
testing and ‘opt-out’ testing programmes being promoted increasingly in Africa (De 
Cock, Bunnell and Mermin 2006; Manzi et al. 2005). The ASSA2002 model allows for 
utilization of VCT through PMTCT and HAART programmes, but it is debatable 
whether this VCT and other ‘opt-out’ testing programmes would be as effective in 
changing behaviour in tested individuals as VCT initiated independently, by individuals 
concerned about their risk of HIV infection. Assumptions about VCT access and 
efficacy may therefore need to be revised in future. 
The ASSA2002 model is an example of how the effects of HIV/AIDS and 
HIV/AIDS interventions can be incorporated into a cohort component projection model. 
The model demonstrates that the age profile of new HIV infections changes over the 
course of the epidemic, and changes in response to prevention and treatment 
programmes. This suggests that the approach of deriving adjustments to a cohort 
component projection model from an independent HIV/AIDS model is problematic if it 
is assumed that the age profile of HIV cases is fixed, as Stover (2004) notes. The 
ASSA2002 model also demonstrates that there is significant age variation in HIV/AIDS 
prevalence, morbidity and mortality. HIV/AIDS models which are based on very broad 
age divisions may therefore be difficult to validate reliably against prevalence and vital 
registration data, if the age distribution of these data differs from that of the population 
modelled. There is thus a strong case for greater integration of demographic modelling 
and disease modelling in the simulation of generalized HIV/AIDS epidemics. 
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